Hensler David M, McConnell Deepika P, Levasseur-Franklin Kimberly E, Greathouse Kasey M
1 Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.
2 Northwestern Memorial Hospital, Chicago, IL, USA.
J Pharm Pract. 2018 Dec;31(6):682-686. doi: 10.1177/0897190017743130. Epub 2017 Nov 21.
: Renal replacement therapy may enhance the elimination of barbiturates. Pentobarbital clearance during continuous venovenous hemofiltration (CVVH) has not been described previously. We report a patient case involving the measurement of serial pentobarbital levels during CVVH and review relevant literature characterizing extracorporeal pentobarbital elimination.
: The following is a retrospective report of a previously healthy 26-year-old woman who sustained a severe traumatic brain injury (TBI) and required administration of pentobarbital on hospital day 0 for intracranial pressure (ICP) control. Given concern for interference with the patient's ongoing neurologic assessments, pentobarbital was discontinued on hospital day 4. The patient's hospital course was complicated by acute kidney injury (AKI), requiring initiation of CVVH on hospital day 5. Daily serum pentobarbital levels were obtained during CVVH.
: While on CVVH, the patient's estimated pentobarbital clearance ranged from 6 to 44 mL/min and the elimination half-life ranged from 17.7 to 65.9 hours. Based on reductions in pentobarbital clearance during CVVH interruption, the elimination of drug was dependent upon extracorporeal removal in this patient. CVVH facilitated pentobarbital elimination in a manner approaching endogenous clearance in healthy individuals.
: We report clinically significant pentobarbital removal by CVVH in a patient with severe TBI. Application of CVVH may expedite reliable neurologic assessments and facilitate the application of clinical brain death examination following pentobarbital exposure.
肾脏替代治疗可能会增强巴比妥类药物的清除。此前尚未描述过持续静静脉血液滤过(CVVH)期间戊巴比妥的清除情况。我们报告了一例患者病例,涉及在CVVH期间连续测量戊巴比妥水平,并回顾了表征体外戊巴比妥清除的相关文献。
以下是对一名先前健康的26岁女性的回顾性报告,该女性遭受了严重的创伤性脑损伤(TBI),并在住院第0天需要使用戊巴比妥来控制颅内压(ICP)。鉴于担心干扰患者正在进行的神经学评估,戊巴比妥在住院第4天停用。患者的住院过程因急性肾损伤(AKI)而复杂化,在住院第5天需要开始CVVH。在CVVH期间每日获取血清戊巴比妥水平。
在进行CVVH期间,患者估计的戊巴比妥清除率为6至44 mL/分钟,消除半衰期为17.7至65.9小时。基于CVVH中断期间戊巴比妥清除率的降低,该患者体内药物的消除依赖于体外清除。CVVH促进戊巴比妥清除的方式接近健康个体的内源性清除。
我们报告了CVVH在一名严重TBI患者中对戊巴比妥具有临床显著的清除作用。CVVH的应用可能会加快可靠的神经学评估,并有助于在戊巴比妥暴露后进行临床脑死亡检查。